ALEMBICLTD2023-04-012023-06-30 ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member ALEMBICLTD2023-06-30 ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member ALEMBICLTD2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member ALEMBICLTD2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member ALEMBICLTD2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 506235 ALEMBICLTD NOTLISTED Alembic Limited Equity 2023-04-01 2024-03-31 2023-08-10 2023-08-02 INR Lakhs First quarter 15:00:00 15:50:00 2023-08-10 2023-08-10 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Standalone 356486000.00 25942000.00 382428000.00 13421000.00 0.00 24712000.00 62654000.00 470000.00 17421000.00 154626000.00 273304000.00 109124000.00 0.00 109124000.00 9564000.00 4728000.00 14292000.00 0.00 94832000.00 0.00 0.00 0.00 0.00 94832000.00 355405000.00 450237000.00 0.00 0.00 513564000.00 2 0.37 0.37 0.00 0.00 0.37 0.37 Cost of Construction 92290000.00 Other Expenses 62336000.00 Active Pharmaceutical Ingredients Business 94369000.00 Real Estate Business 262117000.00 356486000.00 0.00 356486000.00 Active Pharmaceutical Ingredients Business 4528000.00 Real Estate Business 90456000.00 94984000.00 470000.00 -14610000.00 Notes: 1.The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. 2.Exceptional item for the quarter and year ended 31st March, 2023 represents provision made by the Company towards balance of the principal amount (total principal amount being Rs. 2,052.13 lakhs) for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability. Further, as communicated by the Company with the stock exchanges vide its letter dated 15th May, 2023, the Company has deposited Rs. 35 Crores with the Hon’ble Supreme Court of India on 26th May, 2023 and the appeal filed by the Company has been admitted. 3.The figures for quarter ended 31st March 2023 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2023 and year to date unaudited figures up to the third quarter ended 31st December 2022. 4.The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. 109124000.00 Active Pharmaceutical Ingredients Business 1867364000.00 Real Estate Business 3006918000.00 4874282000.00 5155502000.00 10029784000.00 Active Pharmaceutical Ingredients Business 291842000.00 Real Estate Business 599896000.00 891738000.00 397949000.00 1289687000.00 Amount of items that will not be reclassified to profit and loss 400698000.00 400698000.00 45293000.00 0.00